BlueRock Therapeutics

Main focus: iPSC derived cellular therapies

Company stage: Clinical

Diseases: Parkinson's disease, multiple undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Private (acquired, subsidiary of Bayer Pharma)

Location: Cambridge, MA and New York, NY, USA



Partners: Editas Medicine

BlueRock Therapeutics is a company focused on developing stem cell derived therapies. The company applies its research broadly across neurology, cardiology and immunology, with multiple collaborations within these areas. The company has an ongoing technology cross-licensing agreement with Editas Medicine, which allows the company to develop CRISPR-edited stem cell therapies. The company was acquired back in 2019 by Bayer AG.


HashtagBlueRock Therapeutics, LLC.

Search CRISPR Medicine